HK inno.N’s K-CAB debuts in India with Dr. Reddy’s

Korean pharma HK inno.N has launched its gastroesophageal reflux disease (GERD) drug K-CAB (tegoprazan) in India, with Dr. Reddy’s Laboratories set to manage sales and marketing.

The drug, branded locally as PCAB 50 mg, secured Indian approval in May for erosive and non-erosive GERD as well as gastric ulcers. The rollout builds on a 2022 supply deal between HK inno.N and Dr. Reddy that also covers South Africa, Eastern Europe and other emerging markets.

India is the world’s fourth-largest peptic ulcer treatment market, valued at about 1.52 trillion won ($1.1 billion) in 2024. Roughly 38 percent of the population is estimated to have GERD, according to the company’s Wednesday release.

Designated as Korea’s 30th homegrown new drug, K-CAB has generated cumulative domestic prescriptions worth 810.1 billion won since its 2019 debut. HK inno.N said the therapy is the top prescribed peptic ulcer treatment in Korea and has been licensed or exported to 53 countries, with launches in 18 markets including China and parts of Latin America.